Ali Raza
Keine laufenden Positionen mehr
Karriereverlauf von Ali Raza
Ehemalige bekannte Positionen von Ali Raza
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Sosei Co. Ltd.
 Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Direktor/Vorstandsmitglied | 18.01.2011 | - |
| Präsident | - | - | |
| ASTRAZENECA PLC | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Corporate Officer/Principal | - | 16.02.2011 | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01.06.2008 | - |
Ausbildung von Ali Raza
| The University of Manchester | Undergraduate Degree |
| University of London | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 4 |
| Japan | 2 |
| Israel | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| President | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sosei Co. Ltd.
Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
